BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Appoints Dr. Galit Reske as Chief Medical Officer

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, today announced the appointment of Dr. Galit Reske, PhD, as chief medical officer. Dr. Reske brings extensive experience in clinical development, regulatory strategy and global clinical operations, including leadership of CartiHeal’s IDE pivotal study for the Agili-C(TM) cartilage repair implant and support of the product’s U.S. FDA approval in 2022 prior to CartiHeal’s acquisition by Smith+Nephew in 2023.

To view the full press release, visit https://ibn.fm/6kjsX

About Regentis Biomaterials

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW
Breaks Categories: News

Recent Posts

BioMedNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Advances Peptide Innovation and GLP-1 Companion Strategy

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT)…

22 hours ago

BioMedNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) Schedules Third Quarter 2026 Financial Results and Conference Call for Nov. 25

Nanox (NASDAQ: NNOX) announced plans to showcase its medical imaging technologies at the Radiological Society…

1 day ago

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 Operational Highlights and Advances AI-Driven Oncology Pipeline

Lantern Pharma (NASDAQ: LTRN) reported operational highlights and financial results for the third quarter ended…

1 day ago

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Receives USPTO Notice of Allowance for Abuse-Deterrent Fentanyl Patch Brand Names

Nutriband (NASDAQ: NTRB) announced that it received a Notice of Allowance dated Nov. 3, 2026,…

2 days ago

BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal Q2 2027 Financial Results, Highlights Phase 3 Pipeline Progress

This article has been disseminated on behalf of Helus Pharma and may include paid advertising.…

3 days ago